03.04.25 -- CDMOs Bet Big On Asia Expansion. Can Trump Reverse The Tide?

The company is starting small with a pilot to do what most companies avoid altogether — innovating the manufacturing process for a product already on the market.

When it comes to transporting highly sensitive and valuable materials, such as cell therapies, learn how teams can ensure that unique storage and distribution requirements are met.

Developing a robust chromatography platform for AAV8 purification and full capsid enrichment ensures high gene therapy product quality, addressing the challenge of empty capsid removal.

Gene therapy has existed for decades, but the field is not as mature as it may seem. Here, the author provides essential insights and strategies for overcoming gene therapy development challenges.

If you’re hoping to improve your QC toolkit to better accommodate complex modalities like cell and gene therapies, it's time to build a program that accounts for risk and unique product characteristics.

Quality agreements serve a critical role within a CDMO-Sponsor partnership. Review the importance of aligning objectives, quality standards, and compliance frameworks to establish a robust foundation.

By adopting unified digital platforms, implementing standardized data models, and enabling seamless system integrations, see how established continuous digital threads can enhance connectivity.

Consider our advanced sequencing protocols and bioinformatics solutions to achieve comprehensive rAAV characterization, ensuring precise analysis of purity, integrity, and identity.

Here, we examine the benefits of off-the-shelf ionizable lipids and reagent kits that have been pre-developed and pre-optimized for a diverse range of genomic medicine applications.

Immune cell therapies have incredible potential for cancer treatment, and making them more cost effective is a critical consideration for improving patient access and outcomes.

Take a look at the potential of this small molecule screening to enhance AAV9 production and improve gene therapy manufacturing efficiency by leveraging novel compounds.

Low AAV productivity and the absence of platform processes drive up production costs. Discover a scalable suspension manufacturing platform for AAV production.

Finding a manufacturing partner with the capabilities and capacity to offer truly end-to-end development and scale-up can mean the difference between successful commercialization and the end of the road.

Kincell Bio is a trusted manufacturing services partner for cell therapy companies, providing expert services including access to CMC development and clinical manufacturing for cell therapy.

Our gene therapy viral vector process development and manufacturing capabilities are designed to confidently and rapidly progress your products from gene to market through development.

Gain insight into our unparalleled expertise as a leading CDMO in viral vectors, offering top-tier process development, analytical development, and manufacturing solutions.

To jump start iPSC derived therapeutic cell product development; achieve reliable and efficient genome integration with our innovative solutions.